[go: up one dir, main page]

MX2022000589A - Un peptido dirigido al receptor del activador del plasminogeno de la urocinasa. - Google Patents

Un peptido dirigido al receptor del activador del plasminogeno de la urocinasa.

Info

Publication number
MX2022000589A
MX2022000589A MX2022000589A MX2022000589A MX2022000589A MX 2022000589 A MX2022000589 A MX 2022000589A MX 2022000589 A MX2022000589 A MX 2022000589A MX 2022000589 A MX2022000589 A MX 2022000589A MX 2022000589 A MX2022000589 A MX 2022000589A
Authority
MX
Mexico
Prior art keywords
urocinase
upar
activator receptor
peptide directed
plasminogene
Prior art date
Application number
MX2022000589A
Other languages
English (en)
Inventor
Morten Albrechtsen
Anders Christensen
Andreas Kjaer
Karina Juhl
Sorel Kurbegovic
Michael Ploug
Jensen Knud Jørgen
Sørensen Kasper Kildegaard
Original Assignee
Rigshospitalet
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rigshospitalet filed Critical Rigshospitalet
Publication of MX2022000589A publication Critical patent/MX2022000589A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K11/00—Luminescent, e.g. electroluminescent, chemiluminescent materials
    • C09K11/06—Luminescent, e.g. electroluminescent, chemiluminescent materials containing organic luminescent materials
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K2211/00—Chemical nature of organic luminescent or tenebrescent compounds
    • C09K2211/10—Non-macromolecular compounds
    • C09K2211/1018—Heterocyclic compounds
    • C09K2211/1025—Heterocyclic compounds characterised by ligands
    • C09K2211/1029—Heterocyclic compounds characterised by ligands containing one nitrogen atom as the heteroatom

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Materials Engineering (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)

Abstract

La presente invención describe un conjugado de péptido dirigido a uPAR que comprende un fluoróforo, un péptido que se une a uPAR y un grupo enlazador que están conectados por enlaces covalentes, en donde el conjugado de péptido dirigido a uPAR puede usarse como sonda fluorescente en imagen óptica en tiempo real y delimitación de tumores cancerosos o metástasis durante la cirugía.
MX2022000589A 2019-07-16 2020-07-15 Un peptido dirigido al receptor del activador del plasminogeno de la urocinasa. MX2022000589A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE1950898 2019-07-16
PCT/EP2020/070014 WO2021009237A1 (en) 2019-07-16 2020-07-15 A urokinase plasminogen activator receptor-targeting peptide

Publications (1)

Publication Number Publication Date
MX2022000589A true MX2022000589A (es) 2022-05-24

Family

ID=71661859

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022000589A MX2022000589A (es) 2019-07-16 2020-07-15 Un peptido dirigido al receptor del activador del plasminogeno de la urocinasa.

Country Status (12)

Country Link
US (1) US20220401585A1 (es)
EP (1) EP3999094A1 (es)
JP (1) JP7584492B2 (es)
KR (1) KR20220045159A (es)
CN (1) CN114555623B (es)
AU (1) AU2020314065B2 (es)
BR (1) BR112022000164A2 (es)
CA (1) CA3146095A1 (es)
IL (1) IL289732A (es)
MX (1) MX2022000589A (es)
WO (1) WO2021009237A1 (es)
ZA (1) ZA202201889B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240066142A1 (en) * 2021-01-15 2024-02-29 Fluoguide A/S A upar (urokinase plasminogen activator receptor)-targeting conjugate

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1796733A2 (en) 2004-09-29 2007-06-20 GE Healthcare AS Urokinase plasminogen activator receptor targeted contrast agents
EP3733215A1 (en) * 2014-09-17 2020-11-04 Fluoguide A/S Upar targeting peptide for use in peroperative optical imaging of invasive cancer
CN107652358A (zh) * 2017-09-06 2018-02-02 华中师范大学 一种uPAR靶向性多肽、探针和活体分子显像方法

Also Published As

Publication number Publication date
KR20220045159A (ko) 2022-04-12
US20220401585A1 (en) 2022-12-22
CN114555623A (zh) 2022-05-27
AU2020314065A1 (en) 2022-02-17
ZA202201889B (en) 2023-12-20
CN114555623B (zh) 2024-10-25
EP3999094A1 (en) 2022-05-25
WO2021009237A1 (en) 2021-01-21
AU2020314065B2 (en) 2025-12-11
CA3146095A1 (en) 2021-01-21
JP7584492B2 (ja) 2024-11-15
IL289732A (en) 2022-03-01
JP2022544647A (ja) 2022-10-20
BR112022000164A2 (pt) 2022-04-12

Similar Documents

Publication Publication Date Title
CY1123978T1 (el) Σταθερα και διαλυτα αντισωματα που αναστελλουν ton tnf
CY1124435T1 (el) Νουκλεικα οξεα που κωδικοποιουν ανθρωπινα αντισωματα σε sialyl-lewis α
CY1125429T1 (el) Μουτεϊνες ιντερλευκινης-21 και μεθοδοι θεραπευτικης αγωγης
CY1119219T1 (el) Anti-ceacam5 αντισωματα και χρησεις αυτων
CY1124515T1 (el) Συνθεσεις αντι-cgrp και χρησεις αυτων
MX2015011830A (es) Metodos de fabricacion y sintesis de grupos de enlace de aminoacidos conjugados con compuestos usados para la obtencion de imagenes dirigida de los tumores.
MX2021001510A (es) Proteínas de union a nkg2d, cd16, y un antígeno asociado a tumores.
CO2020000357A2 (es) Receptores de células t novedosos, e inmunoterapia usando los mismos
PH12020551689A1 (en) Her2-targeting antigen binding molecules comprising 4-1bbl
CY1118979T1 (el) Αντισωματα που κατευθυνονται εναντι her-3 και χρησεις αυτων
EA201890294A1 (ru) Химерный полипептидный комплекс и способы его получения и применения
EA201890613A1 (ru) Полипептиды, связывающие cd3
CY1119893T1 (el) Προϊοντα συζευξης cc-1065 αναλογων και διλειτουργικων συνδετων
CY1119591T1 (el) Πρωτεϊνες ειδικης συνδεσης και χρησεις αυτων
MX2021006991A (es) Ligandos peptidicos biciclicos especificos para metaloproteasa tipo 1 de membrana (mt1-mmp).
AR110114A1 (es) ANTICUERPOS CONTRA b-AMILOIDE PIROGLUTAMATO Y SUS USOS
AR109355A2 (es) Moléculas de unión al receptor ox40 humano
WO2016187220A3 (en) Anti-ror1 antibodies
CL2019002953A1 (es) Anticuerpo anti-pd-l1 y uso del mismo.
AR078254A1 (es) Inmunoglobulinas con dominio variable dual y usos de las mismas
EA201790404A1 (ru) Макропиноцитозирующие человеческие анти-cd46 антитела и таргетная терапия рака
CY1115798T1 (el) Μεθοδος για τη διαγνωση καρκινων που εκφραζουν μια κολοβωμενη παραλλαγη του υποδοχεα her2
AR080301A1 (es) Anticuerpos e inmunoconjugados del receptor 1 de folato y sus usos
EA202090800A1 (ru) Новые анти-cd3-эпсилон антитела
CO6220870A2 (es) Prediccion de respuesta a un inhibidor a un inhibidor de dimerizacion her basado en expresion de her3 bajo